Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2020

1.
2.

Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines [Internet].

Li KX, Picheca L.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Sep 26.

3.

JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.

Anselmo F, Tatomir A, Boodhoo D, Mekala AP, Nguyen V, Rus V, Rus H.

Clin Immunol. 2019 Nov 4:108297. doi: 10.1016/j.clim.2019.108297. [Epub ahead of print]

PMID:
31698073
4.

Glatiramer acetate attenuates renal ischemia reperfusion injury in rat model.

Nezamoleslami S, Sheibani M, Dehpour AR, Mobasheran P, Shafaroodi H.

Exp Mol Pathol. 2019 Nov 4:104329. doi: 10.1016/j.yexmp.2019.104329. [Epub ahead of print]

PMID:
31697931
5.

Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis.

Vázquez-Leyva S, Vallejo-Castillo L, López-Morales CA, Herbert-Pucheta JE, Zepeda-Vallejo LG, Velasco-Velázquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E.

Anal Chem. 2019 Oct 30. doi: 10.1021/acs.analchem.9b02873. [Epub ahead of print]

PMID:
31664820
6.

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.

Kapica-Topczewska K, Tarasiuk J, Collin F, Brola W, Chorąży M, Czarnowska A, Kwaśniewski M, Bartosik-Psujek H, Adamczyk-Sowa M, Kochanowicz J, Kułakowska A.

PLoS One. 2019 Oct 24;14(10):e0223863. doi: 10.1371/journal.pone.0223863. eCollection 2019.

7.

Glatiramer Acetate.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2018 Mar 14.

8.

Multiple Sclerosis Agents.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2015 Jul 1.

9.

[The pegylated form of interferon beta in the treatment of multiple sclerosis].

Melnikov MV, Kasatkin DS, Volkov AI, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(8):136-141. doi: 10.17116/jnevro2019119081136. Russian.

PMID:
31626182
10.

Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs.

Skovdal SM, Christiansen SH, Johansen KS, Viborg O, Bruun NH, Jensen-Fangel S, Holm IE, Vorup-Jensen T, Petersen E.

PLoS One. 2019 Oct 10;14(10):e0223647. doi: 10.1371/journal.pone.0223647. eCollection 2019.

11.

Assessing the Similarity between Random Copolymer Drug Glatiramer Acetate by Using LC-MS Data Coupling with Hypothesis Testing.

Wu HY, Ma MC, Pan YY, Shih CL, Zgoda V, Li CS, Lin LC, Liao PC.

Anal Chem. 2019 Nov 1. doi: 10.1021/acs.analchem.9b02488. [Epub ahead of print]

PMID:
31590482
12.

CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients.

Tahrali I, Kucuksezer UC, Akdeniz N, Altintas A, Uygunoglu U, Aktas-Cetin E, Deniz G.

Immunol Lett. 2019 Oct 4;216:63-69. doi: 10.1016/j.imlet.2019.10.006. [Epub ahead of print]

PMID:
31589897
13.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

JAMA Neurol. 2019 Oct 7. doi: 10.1001/jamaneurol.2019.3365. [Epub ahead of print]

PMID:
31589278
14.

Vitamin D enhances responses to interferon-β in MS.

Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S, Reder AT.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 3;6(6):e622. doi: 10.1212/NXI.0000000000000622. Print 2019 Nov.

15.

Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity.

De Masi R, Orlando S, De Donno A.

Ann Clin Transl Neurol. 2019 Sep 30. doi: 10.1002/acn3.50883. [Epub ahead of print]

16.

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis.

Saleem S, Anwar A, Fayyaz M, Anwer F, Anwar F.

Cureus. 2019 Jul 26;11(7):e5246. doi: 10.7759/cureus.5246. Review.

17.

Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract Intended for Batch Release.

Carballo-Uicab G, Linares-Trejo JE, Mellado-Sánchez G, López-Morales CA, Velasco-Velázquez M, Pavón L, Estrada-Parra S, Pérez-Tapia SM, Medina-Rivero E.

Molecules. 2019 Sep 20;24(19). pii: E3426. doi: 10.3390/molecules24193426.

18.

Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate.

Arends RJ, Wang D, Buurman M, Luten J, Koper NP, Wolf C, Scheren M.

Pharmazie. 2019 Aug 1;74(8):449-461. doi: 10.1691/ph.2019.9515.

PMID:
31526436
19.

Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments.

Gklinos P, Papadopoulos D, Mitsikostas DD.

Mult Scler Relat Disord. 2019 Sep 9;36:101389. doi: 10.1016/j.msard.2019.101389. [Epub ahead of print]

PMID:
31525626
20.

Myeloperoxidase Molecular MRI Reveals Synergistic Combination Therapy in Murine Experimental Autoimmune Neuroinflammation.

Li A, Wu Y, Pulli B, Wojtkiewicz GR, Iwamoto Y, Wang C, Li JH, Ali M, Feng X, Yao Z, Chen JW.

Radiology. 2019 Oct;293(1):158-165. doi: 10.1148/radiol.2019182492. Epub 2019 Sep 3.

Supplemental Content

Loading ...
Support Center